At Novo Nordisk, we are dedicated to making obesity a healthcare priority. Changing ObesityTM is our long-term commitment to improve the lives of people with obesity by changing how the world sees, prevents and treats obesity.
Our focus areas are:
We work to build healthier environments to enable improved
We work to foster empathy for people with obesity and make obesity a healthcare priority
We work to ensure people with obesity have access to science-based and comprehensive care
We work both independently and with our partners to advance medical management through education, advocacy, patient support and improved access to care.
Truth About Weight®
To help patients prepare for a productive conversation with their healthcare provider, TruthAboutWeight.com provides information around the science behind weight loss and provides tools to help assess weight management history, motivations, and triggers.
Learn more at truthaboutweight.com
Obesity Care Week
Obesity Care Week was founded in 2015 to change the way society cares about obesity. This public awareness initiative aims to provide science and clinically based education on obesity and advocate for access to affordable and comprehensive care.
Learn more at obesitycareweek.org
World Obesity Day
On World Obesity Day, held on March 4, organizations from across the globe celebrate a unified campaign aimed at inspiring global change in policy making, attitudes and action around obesity.
Learn more at obesityday.worldobesity.org
Obesity Care Advocacy Network
Created to elevate obesity on the national agenda, the Obesity Care Advocacy Network unites and aligns obesity stakeholders and the community around obesity-related education, policy, and legislative efforts.
Learn more at obesitycareadvocacynetwork.com
To understand the what and why behind barriers to care, the Awareness Care and Treatment In Obesity management Study, was the first US nationwide study to investigate barriers to obesity management from the perspective of employers, healthcare professionals, and people with obesity.
Learn more at actionstudy.com
© 2020 Novo Nordisk All rights reserved. US20NNG00007 March 2020